BGTSBasic Graduate Theological Studies
References in periodicals archive ?
The number of prescriptions, quantity dispensed and costs of BGTS were determined for each year and for each quantity limit scenario from 2004 to 2012.
In this large, population-based study spanning two provinces in Canada, we found the prevalence of BGTS use among patients with diabetes is high, resulting in substantial annual costs to public payers ($104 million and $23 million in Ontario and BC respectively).
The prevalence of diabetes continues to rise as the population ages, (1) and the increasing use of BGTS among patients with diabetes not receiving insulin (2) has considerable financial implications for public payers.
This research suggests that both reducing reimbursed quantity limits and negotiating lower unit costs for BGTS could have a considerable impact on utilization and costs irrespective of differences in drug plan design.